P‐TS‐24 | Design of ReCePI, a Randomized, Double‐Blinded, Ph…
Emerging
0
Citations0
Refs2023
Year
Search Works
Work Details
- DOI 10.1111/trf.361_17554
- OpenAlex ID W4387572211
- Type Article
- Language EN
- Published 01 Oct 2023
- Volume 63 (S5)
- Source Transfusion
- Publisher Wiley
- Countries 1
- Institutions 1
- Added 13 Oct 2023
- Updated 30 Oct 2026
External Links
MENU
0
P‐TS‐24 | Design of ReCePI, a Randomized, Double‐Blinded, Phase III Study to Evaluate the Efficacy and Safety of Pathogen Reduced RBCs in Complex Cardiac Surgery
Article 2023 EN Bronze
Pathogen reduction of RBCs (PR-RBCs) treated with amustaline/glutathione is an investigational process designed to reduce transfusion-transmitted infection and TA-GVHD. The Red Cell Pathogen Inactivation (ReCePI) study aims to evaluate the efficacy and safety of PR-RBC transfusions for support of acute anemia. An acute kidney injury (AKI) endpoint in cardiovascular surgery (CVS) was selected based…
0
Citations
0
References
5
Authors
0.00
FWCI
Topics
Keywords
UN Sustainable Development Goals
1 SDGsAuthors & Affiliations
5 authors| # | Author | Institutions | ORCID |
|---|---|---|---|
| 1 | Richard J. Benjamin | Cerus (United States) (US) | |
| 2 | John P. Pitman | Cerus (United States) (US) | |
| 3 | Laurence Corash | Cerus (United States) (US) | |
| 4 | Jeanne Varrone | Cerus (United States) (US) | — |
| 5 | Nina Mufti | Cerus (United States) (US) | — |
Related Works
10Data: OpenAlex